Global Lung Cancer Diagnostics Market Size & Trends Report Segmented by Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer), Test Type (CA, HER2, Others), End-user (Hospitals, Diagnostic Centers, Others) & Regional Forecasts to 2030
The lung cancer diagnostics market encompasses tools, techniques, and services for detecting lung cancer, including imaging, biopsy, molecular diagnostics, and biomarker analysis. It is projected to grow at a CAGR of 7% in the next five years. This growth is driven by rising lung cancer incidence, advances in diagnostic technologies, increasing awareness for early detection, and expanding accessibility to precision medicine. However, the market faces challenges such as the high costs of advanced diagnostic tools and limited access to healthcare in underdeveloped regions. To learn more about the research report, download a sample report.
Report Overview
Lung cancer diagnostics involves various methods and technologies to detect, confirm, and analyze lung cancer, enabling effective treatment decisions. Imaging techniques such as X-rays, CT scans, and PET scans are often the first step to identify tumours and assessing their spread. Tissue biopsies, including bronchoscopy and needle biopsies, provide definitive confirmation of cancer by analyzing cellular samples. Advances in molecular diagnostics, like Next-Generation Sequencing (NGS) and liquid biopsy, allow for detecting genetic mutations (e.g., EGFR, ALK, KRAS) critical for personalized treatment approaches. 
To learn more about the research report, download a sample report.
Rising Focus on Early Detection of Lung Cancer
Early detection of lung cancer significantly improves survival rates, as it allows for timely intervention and treatment before the disease advances. Governments and healthcare organizations are increasingly investing in screening programs, particularly for high-risk groups such as smokers and individuals with a family history of cancer. The adoption of low-dose CT (LDCT) as a screening tool has gained prominence, supported by numerous clinical studies proving its efficacy in detecting lung cancer at an earlier, more treatable stage. Public health campaigns emphasizing the benefits of early screening, combined with the availability of reimbursement for screening tests in developed economies, have further accelerated adoption. This focus on early detection not only drives the market but also aligns with the global shift toward preventative healthcare strategies aimed at reducing the burden of late-stage cancer treatments. 
To learn more about the research report, download a sample report.
Biomarker Testing in Lung Cancer Diagnostics
Biomarker testing has emerged as a groundbreaking advancement in lung cancer diagnostics, enabling personalized and precise treatment approaches. Molecular and genetic testing techniques, such as next-generation sequencing (NGS) and liquid biopsy, allow clinicians to identify specific mutations (e.g., EGFR, ALK, ROS1) and tailor therapies accordingly. Liquid biopsies, in particular, are non-invasive and provide real-time insights into tumour dynamics, enhancing their appeal for routine monitoring. Additionally, advances in artificial intelligence (AI) are transforming biomarker interpretation, improving diagnostic accuracy and speed. The integration of AI with molecular diagnostics platforms facilitates automated analysis of complex datasets, ensuring reliable and reproducible results. These advancements not only boost diagnostic efficiency but also play a critical role in advancing precision oncology, making biomarker testing a cornerstone of lung cancer diagnostics. Â Â
Competitive Landscape Analysis
The global lung cancer diagnostics market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific; Agilent Technologies; Qiagen; Abbott; Bio-Rad Laboratories, Inc.; Neogenomics Laboratories; Myriad Genetics, Inc.; and Illumina Inc. among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion. Â
Report Scope
| Report Scope | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 – 2030 |
| Growth Rate | 7% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Cancer Type, Test Type and End-user |
| Regional Scope |
|
| Key Companies Mapped | F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific; Agilent Technologies; Qiagen; Abbott; Bio-Rad Laboratories, Inc.; Neogenomics Laboratories; Myriad Genetics, Inc.; and Illumina Inc. among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Market Segmentation
This report by Medi-Tech Insights provides the size of the global lung cancer diagnostics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on cancer type, test type and end-user.
- Market Size & Forecast (2023-2030), By Cancer Type, USD Million
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Market Size & Forecast (2023-2030), By Test Type, USD Million
- CA Test
- HER2 Test
- ALK Test
- Angiogenesis Inhibitors
- EGFR Mutation Test
- KRAS Mutation Test
- Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic Centers
- Others
- Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
- North America
Key Strategic Questions Addressed
- What is the market size & forecast of the lung cancer diagnostics market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the lung cancer diagnostics market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction​
- Market Scope​
- Market Definition​
- Segments Covered​
- Regional Segmentation​
- Research Timeframe​
- Currency Considered​
- Study Limitations​
- Stakeholders​
- List of Abbreviations​
- Key Conferences and Events (2025-2026)​
- Research Methodology​
- Secondary Research​
- Primary Research​
- Market Estimation​
- Bottom-Up Approach​
- Top-Down Approach​
- Market Forecasting​
- Executive Summary
- Lung Cancer Diagnostics Market Snapshot (2025-2030)​
- Segment Overview​
- Regional Snapshot​
- Competitive Insights ​
- Market Overview
- Market Dynamics
- Drivers
- Rising prevalence of lung cancer globally
- Advancements in molecular diagnostics and liquid biopsy
- Increasing adoption of precision medicine for targeted therapies
- Growing awareness of early detection and government screening initiatives
- Improved healthcare access in emerging markets
- Restraints​
- Complex regulatory landscape
- High costs of advanced diagnostic tools
- Variability in test accuracy and diagnostic outcomes across different platforms
- Opportunities​
- Rising demand for non-invasive diagnostic methods like liquid biopsy
- Development of AI-based tools enhancing imaging diagnostics (e.g., CT scans)
- Increasing research collaborations to develop novel biomarker-based diagnostics
- Growth in personalized medicine and companion diagnostics
- Key Market Trends​
- Growing adoption of NGS for comprehensive lung cancer genomic profiling
- Rising role of companion diagnostics in targeted therapies for biomarkers like EGFR, ALK, and HER2
- Unmet Market Needs​
- Industry Speaks​
- Global Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By Cancer Type, USD Million
- Introduction​
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Global Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By Test Type, USD Million
- Introduction​
- CA Test
- HER2 Test
- ALK Test
- Angiogenesis Inhibitors
- EGFR Mutation Test
- KRAS Mutation Test
- Global Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By End-user, USD Million
- Introduction​
- Hospitals
- Diagnostic Centers
- Others
- Global Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction​
- North America Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By Country, USD Million​
- US​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Canada​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- US​
- Europe Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By Country, USD Million​
- UK ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Germany ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Italy ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Spain ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Rest of Europe ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- UK ​
- Asia Pacific (APAC) Lung Cancer Diagnostics Market Size & Forecast (2023-2030), By Country, USD Million​
- China ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Japan ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- India ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Rest of Asia Pacific ​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- China ​
- Latin America (LATAM) Lung Cancer Diagnostics Market Size & Forecast (2023-2030), USD Million​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​​
- Middle East & Africa (MEA) Lung Cancer Diagnostics Market Size & Forecast (2023-2030), USD Million​
- Market Size & Forecast, By Cancer Type (USD Million)​
- Market Size & Forecast, By Test Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​​
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2024)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Company Profiles*(Business Overview, Financial Performance**, Products Offered, Recent Developments)
-
- Hoffmann-La Roche Ltd
- Thermo Fisher Scientific
- Agilent Technologies
- Qiagen
- Abbott
- Bio-Rad Laboratories, Inc.
- Neogenomics Laboratories
- Myriad Genetics, Inc.
- Illumina Inc.
- Other Prominent Players
  Note: *Indicative list
 **For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals, Diagnostic Centers and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
